Lu-Dotatate Shows Unprecedented PFS in Midgut NETs


Lu-Dotatate demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR in patients with progressive, metastatic midgut neuroendocrine tumors.

Jonathan Strosberg, MD

The radiopharmaceutical Lu-Dotatate (177Lutetium DOTATATE; Lutathera) demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR (60 mg) in patients with progressive, metastatic midgut neuroendocrine tumors (NETs), according to results from NETTER-1 trial presented by Jonathan Strosberg, MD, at the 2015 NANETS Symposium.

"The findings were, in my opinion, extraordinarily impressive, the median progression-free survival improved by nearly 80%, which is fairly unprecedented in oncologic studies," said Strosberg, a medical oncologist and researcher at the Moffitt Cancer Center. "The finding is important because limited therapeutic options exist for such patients, who comprise 20% to 45% of neuroendocrine tumor cases."

The NETTER-1 trial is the first prospective, randomized, phase III study for patients with midgut NETs, specifically those in the ileum and cecum. Patients in the trial had progressed on prior therapy with octreotide at 30 mg and had inoperable, somatostatin receptor positive tumors.

Those randomized to the Lu-Dotatate arm received the therapy at 7.4 GBq in 4 doses over eight weeks in combination with 30 mg of octreotide LAR every 28 days. In the comparator arm, octreotide LAR was administered alone at 60 mg every four weeks. Patient in the Lu-Dotatate arm also received renal protection via amino acid solution infusion.

Interim results showed the median progression-free survival had not been reached for Lu-Dotatate compared with 8.4 months for octreotide (HR, 0.21; 95% CI, 0.13-0.34; P <.0001). Disease progression had occurred in 4% of patients in the Lu-Dotatate group and 24% of the octreotide group.

"The median time to progression was 8.7 months with high-dose octreotide, which was the control arm, and was not yet reached in the Lutetium arm, with a median follow up of nearly a year and a half," Strosberg said. "It is looking like the ultimate outcome, median progression-free survival, will probably be around the 40-month range."

The objective response rate with Lu-Dotatate was 19% compared with 3%. One patient in the radiopharmaceutical arm achieved a complete response compared with none in the octreotide arm. Stable disease was almost the same for both groups.

For the secondary endpoint of overall survival, 13 patients had died in the Lu-Dotatate arm compared with 22 in the octreotide group. The P value for this trend toward improvement in overall survival was .018; however, the threshold for statistical significant at the preliminary analysis was less than .001, Strosberg said.

"As far as overall survival, which was the secondary endpoint, there was a very strong trend toward improvement in overall survival," he told OncLive. "The results are extremely encouraging for survival, not quite meeting the exacting threshold for preliminary survival."

Safety data from the NETTER-1 trial confirmed favorable results of the preceding phase I/II studies. Serious adverse events related to treatment were 9% for Lu-Dotatate and 1% for octreotide. Withdrawals due to adverse events were 5% for Lu-Dotatate and did not occur in patients treated with octreotide, Strosberg said.

The ongoing study includes an 18-month accrual period (completed) plus a 5-year follow-up, starting from the last patient’s randomization on February 2015. Patients remain under treatment until disease progression, unacceptable toxicity or inability/unwillingness to comply with study requirements. Main secondary endpoints are objective response rate, overall progression, time to progression, safety, tolerability and health-related quality of life, which will continue to be assessed. In a subset of patients, dosimetry, pharmacokinetics, and ECG evaluations are also performed.

The drug's maker, Advanced Accelerator Applications, says Lu-Dotatate is the most advanced candidate in development of peptide receptor radionuclide therapy (PRRTs), which target tumors with radiolabelled somatostatin analog peptides. In April 2015, the FDA granted a fast track designation to Lu-Dotatate for the treatment of inoperable progressive midgut NETs. This designation is meant to facilitate the development of novel therapies.

Strosberg J, Wolin E, Chasen B, et al. 177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors: Results of the Phase III NETTER-1 Trial. Presented at: 2015 NANETS Symposium; October 15-17; Austin, TX. Abstract C39.


View more from the 2015 NANETS Symposium

Related Videos
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD
Kevin Kalinsky, MD, MS
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center